Format

Send to

Choose Destination
J Vasc Surg. 2019 Mar 2. pii: S0741-5214(19)30059-X. doi: 10.1016/j.jvs.2018.10.120. [Epub ahead of print]

Association between statin use and perioperative mortality after aortobifemoral bypass in patients with aortoiliac occlusive disease.

Author information

1
Johns Hopkins Bayview Vascular and Endovascular Research Center, Baltimore, Md.
2
Division of Vascular and Endovascular Surgery, University of California San Diego, La Jolla, Calif.
3
Division of Vascular and Endovascular Surgery, University of California San Diego, La Jolla, Calif. Electronic address: mmalas@ucsd.edu.

Abstract

OBJECTIVE:

The benefit of statins in reducing perioperative cardiovascular events in patients undergoing suprainguinal bypass is still controversial. The purpose of this study was to evaluate the association between statin use and perioperative mortality in patients undergoing aortobifemoral bypass (ABFB) for aortoiliac occlusive disease.

METHODS:

We retrospectively analyzed all patients who had ABFB in the American College of Surgeons National Surgical Quality Improvement Program data set from 2011 to 2016. Univariable (t-test, χ2 test, or Fisher exact test) and multivariable logistic regression analyses were used to compare patients' characteristics and the primary outcome (30-day mortality) between statin users and nonstatin users. Propensity score matching between statin users and nonusers was also performed on the basis of variables that were different between the two groups.

RESULTS:

A total of 4445 patients underwent ABFB. Of those, 3032 (68.2%) were taking statins. Compared with non-statin users, statins users were older (median [interquartile range], 67 years [59-74 years] vs 63 years [56-72 years]; P < .01) and more likely to be diabetic (31% vs 16%) and hypertensive (84% vs 63%) and to have a history of chronic obstructive pulmonary disease (20% vs 17%; all P < .05). Statin users had lower rates of 30-day mortality (3.4% vs 4.7%; P = .03) and renal complications (2.5% vs 3.7%; P = .04) compared with nonstatin users. After adjustment for patients' demographics (age, sex, race), comorbidities (diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, dialysis, bleeding disorder), smoking, clinical presentation (claudication vs critical limb ischemia), and elective surgery status, statin use was associated with 32% reduction in 30-day mortality (odds ratio, 0.68; 95% confidence interval, 0.47-0.96; P = .03). Propensity score matching showed similar results (odds ratio, 0.63; 95% confidence interval, 0.41-0.95; P = .03).

CONCLUSIONS:

This is the largest study to date demonstrating an association between preoperative statin use and lower 30-day mortality after ABFB for aortoiliac occlusive disease. This study highlights an area of potential quality improvement as one-third of the patients undergoing this procedure are not receiving statins.

KEYWORDS:

Aortobifemoral bypass; Aortoiliac occlusive disease; Statins

PMID:
30837182
DOI:
10.1016/j.jvs.2018.10.120

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center